SG11201505301XA - Vaccines with higher carbohydrate antigen density and novel saponin adjuvant - Google Patents

Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Info

Publication number: SG11201505301XA
Authority: SG; Singapore
Prior art keywords: vaccines; carbohydrate antigen; antigen density; saponin adjuvant; higher carbohydrate
Prior art date: 2013-01-04

Application number

SG11201505301XA

Inventor

Wei Han Lee

Nan-Hsuan Wang

Chung Hao Chang

Yih-Huang Hsieh

Cheng-Chi Wang

Yu-Hsin Lin

Yu-Chen Lin

I-Ju Chen

Cheng Der Tony Yu

Original Assignee

Obi Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-01-04

Filing date

2014-01-06

Publication date

2015-08-28

2014-01-06 Application filed by Obi Pharma Inc filed Critical Obi Pharma Inc

2015-08-28 Publication of SG11201505301XA publication Critical patent/SG11201505301XA/en

Links

239000002671 adjuvant Substances 0.000 title 1
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
150000001720 carbohydrates Chemical class 0.000 title 1
239000001397 quillaja saponaria molina bark Substances 0.000 title 1
229930182490 saponin Natural products 0.000 title 1
150000007949 saponins Chemical class 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/256—Polyterpene radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

SG11201505301XA 2013-01-04 2014-01-06 Vaccines with higher carbohydrate antigen density and novel saponin adjuvant SG11201505301XA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361748880P	2013-01-04	2013-01-04
PCT/US2014/010310 WO2014107652A2 (en)	2013-01-04	2014-01-06	Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Publications (1)

Publication Number	Publication Date
SG11201505301XA true SG11201505301XA (en)	2015-08-28

Family

ID=51062556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201505301XA SG11201505301XA (en)	2013-01-04	2014-01-06	Vaccines with higher carbohydrate antigen density and novel saponin adjuvant

Country Status (17)

Country	Link
US (2)	US10517936B2 (en)
EP (2)	EP3792272A1 (en)
JP (2)	JP6359561B2 (en)
KR (2)	KR101806370B1 (en)
CN (2)	CN105026413B (en)
AU (2)	AU2014203977B2 (en)
CA (2)	CA3044471C (en)
CL (2)	CL2015001900A1 (en)
ES (1)	ES2843509T3 (en)
HK (1)	HK1213266A1 (en)
IL (2)	IL239785B (en)
PH (1)	PH12015501519A1 (en)
RU (1)	RU2015131033A (en)
SG (1)	SG11201505301XA (en)
TW (2)	TWI572356B (en)
WO (1)	WO2014107652A2 (en)
ZA (1)	ZA201504813B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2015131033A (en)	2013-01-04	2017-02-09	Оби Фарма, Инк.	HIGH-DENSITY VACCINES FOR CARBOHYDRATE ANTIGEN PLACEMENT AND THE NEW SAPONIN ADJUVANT
EP3119424A4 (en)	2014-03-19	2017-09-13	MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital	Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
WO2016040369A2 (en) *	2014-09-08	2016-03-17	Academia Sinica	HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US20170348414A1 (en) *	2014-09-15	2017-12-07	Wayne State University	Novel synthetic anticancer, antifungal, and antibacterial vaccines
JP6774941B2 (en) *	2014-09-15	2020-10-28	オービーアイファーマ，インコーポレイテッド	Immunogenic / Therapeutic Sugar Conjugate Compositions and Their Use
WO2017041027A1 (en) *	2015-09-04	2017-03-09	Obi Pharma, Inc.	Glycan arrays and method of use
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
KR20180121786A (en)	2016-03-29	2018-11-08	오비아이 파머 인코퍼레이티드	Antibodies, pharmaceutical compositions and methods
KR20230110820A (en) *	2016-04-22	2023-07-25	오비아이 파머 인코퍼레이티드	Cancer immunotherapy by immune activation or immune modulation via globo series antigens
CN110072545A (en)	2016-07-27	2019-07-30	台湾浩鼎生技股份有限公司	Immunogenicity/therapeutic glycan pool object and application thereof
KR102528998B1 (en)	2016-07-29	2023-05-03	오비아이 파머 인코퍼레이티드	Human Antibodies, Pharmaceutical Compositions and Methods
JP2019535731A (en)	2016-11-21	2019-12-12	オービーアイファーマ，インコーポレイテッド	Conjugated biological molecules, pharmaceutical compositions and methods
CN112513635B (en) *	2018-05-11	2024-04-16	台湾浩鼎生技股份有限公司	Method for predicting immune response in human body
US11203645B2 (en)	2018-06-27	2021-12-21	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
CN114805454B (en) *	2021-01-21	2023-07-18	中国科学院生态环境研究中心	Alpha-galactose ceramide compound, and preparation method and application thereof
CN114259559B (en) *	2021-12-28	2024-03-19	天津科技大学	Synthetic tumor vaccine containing alpha-GalCer endogenous adjuvant
CN114306586A (en) *	2022-01-04	2022-04-12	天津科技大学	Tumor vaccine based on TF antigen and chitosan oligosaccharide endogenous adjuvant, method and application

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5244657A (en)	1987-11-24	1993-09-14	Connaught Laboratories Limited	Genetic detoxification of pertussis toxin
US5332583A (en)	1987-11-24	1994-07-26	Connaught Laboratories Limited	Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en)	1987-11-24	1994-10-25	Connaught Laboratories Limited	Genetic detoxification of pertussis toxin
GB8727489D0 (en)	1987-11-24	1987-12-23	Connaught Lab	Detoxification of pertussis toxin
US5221618A (en)	1987-11-24	1993-06-22	Connaught Laboratories Limited	Genetic detoxification of pertussis toxin
DE69434079T2 (en)	1993-03-05	2005-02-24	Wyeth Holdings Corp.	Plasmid for the production of CRM protein and diphtheria toxin
US6544952B1 (en)	1994-03-15	2003-04-08	Sloan-Kettering Institute For Cancer Research	Synthesis of glycoconjugates of the globo-H epitope and uses thereof
ES2308962T3 (en) *	1995-06-07	2008-12-16	Glaxosmithkline Biologicals S.A.	VACCINES UNDERSTANDING A CONJUGATE OF ANTIGEN POLISACARIDO-PROTEINA TRANSPORADORA AND A PROTEIN FREE CARRIER.
KR19990022680A (en) *	1995-06-23	1999-03-25	장 스테판느	Vaccines comprising polysaccharide antigen-carrier protein conjugates and free carrier proteins
US6231859B1 (en)	1996-12-02	2001-05-15	Aquila Biopharmaceuticals, Inc.	Saponin adjuvant compositions
EP0996451B1 (en)	1997-05-20	2005-01-05	Galenica Pharmaceuticals, Inc.	Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en)	1997-05-20	2000-06-27	Galenica Pharmaceuticals, Inc.	Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US7018637B2 (en)	1998-02-23	2006-03-28	Aventis Pasteur, Inc	Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
DE10130545A1 (en)	2001-06-25	2003-01-09	Bosch Gmbh Robert	Air conditioning system operating method
JP2004534088A (en)	2001-07-06	2004-11-11	スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ	Multivalent conjugate vaccine for cancer
EP1467755A1 (en) *	2001-12-21	2004-10-20	Antigenics Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20060035267A1 (en)	2003-04-09	2006-02-16	Livingston Philip O	Optimal polyvalent vaccine for cancer
CA2531023C (en)	2003-07-04	2013-04-30	Institut Pasteur	Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
GB0323965D0 (en) *	2003-10-13	2003-11-19	Glaxosmithkline Biolog Sa	Immunogenic compositions
EP1848672A4 (en)	2005-02-01	2009-11-04	Morphosys Ag	Libraries and methods for isolating antibodies
US20080260774A1 (en)	2007-04-13	2008-10-23	Chi-Huey Wong	Alpha-galactosyl ceramide analogs and their use as immunotherapies
US8324742B2 (en) *	2008-04-01	2012-12-04	Texas Instruments Incorporated	Alignment mark for opaque layer
KR102256410B1 (en)	2008-04-08	2021-05-26	슬로안-케테링인스티튜트퍼캔서리서치	Triterpene saponins, methods of synthesis, and uses thereof
CA2728344A1 (en) *	2008-06-16	2010-01-14	Academia Sinica	Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
US7928077B2 (en)	2008-07-11	2011-04-19	Academia Sinica	Alpha-galactosyl ceramide analogs and their use as immunotherapies
KR101677279B1 (en) *	2009-06-16	2016-11-29	아카데미아 시니카	Globo h and related anti-cancer vaccines with novel glycolipid adjuvants
JP6050227B2 (en) *	2010-06-11	2016-12-21	スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ	Multivalent glycopeptide constructs and uses thereof
CA2867700A1 (en)	2012-03-23	2013-09-26	Memorial Sloan-Kettering Cancer Center	Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
RU2015131033A (en)	2013-01-04	2017-02-09	Оби Фарма, Инк.	HIGH-DENSITY VACCINES FOR CARBOHYDRATE ANTIGEN PLACEMENT AND THE NEW SAPONIN ADJUVANT
ITMI20130142A1 (en)	2013-01-31	2014-08-01	Biosynth Srl	GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED
CN104693305A (en)	2013-12-04	2015-06-10	苏州中赢医疗科技有限公司	Anti-human glycosphingolipid Globo-H monoclonal antibody and preparation method and application thereof

2014
- 2014-01-06 RU RU2015131033A patent/RU2015131033A/en not_active Application Discontinuation
- 2014-01-06 KR KR1020157020818A patent/KR101806370B1/en active IP Right Grant
- 2014-01-06 AU AU2014203977A patent/AU2014203977B2/en active Active
- 2014-01-06 CA CA3044471A patent/CA3044471C/en active Active
- 2014-01-06 JP JP2015551806A patent/JP6359561B2/en active Active
- 2014-01-06 TW TW103100353A patent/TWI572356B/en active
- 2014-01-06 TW TW105141502A patent/TWI611810B/en active
- 2014-01-06 CN CN201480003725.4A patent/CN105026413B/en active Active
- 2014-01-06 SG SG11201505301XA patent/SG11201505301XA/en unknown
- 2014-01-06 CA CA2897084A patent/CA2897084C/en active Active
- 2014-01-06 EP EP20187437.7A patent/EP3792272A1/en active Pending
- 2014-01-06 CN CN202010234884.2A patent/CN111499679B/en active Active
- 2014-01-06 KR KR1020177034329A patent/KR102084301B1/en active IP Right Grant
- 2014-01-06 WO PCT/US2014/010310 patent/WO2014107652A2/en active Application Filing
- 2014-01-06 EP EP14735355.1A patent/EP2941436B1/en active Active
- 2014-01-06 US US14/758,319 patent/US10517936B2/en active Active
- 2014-01-06 ES ES14735355T patent/ES2843509T3/en active Active
2015
- 2015-07-03 CL CL2015001900A patent/CL2015001900A1/en unknown
- 2015-07-03 ZA ZA2015/04813A patent/ZA201504813B/en unknown
- 2015-07-03 CL CL2015001902A patent/CL2015001902A1/en unknown
- 2015-07-03 PH PH12015501519A patent/PH12015501519A1/en unknown
- 2015-07-05 IL IL239785A patent/IL239785B/en active IP Right Grant
2016
- 2016-02-01 HK HK16101118.7A patent/HK1213266A1/en unknown
2017
- 2017-01-17 AU AU2017200312A patent/AU2017200312B2/en active Active
2018
- 2018-04-16 IL IL258728A patent/IL258728B/en active IP Right Grant
- 2018-06-20 JP JP2018117319A patent/JP6781204B2/en active Active
2019
- 2019-11-01 US US16/671,395 patent/US11752204B2/en active Active

Also Published As

Publication number	Publication date
AU2017200312B2 (en)	2018-05-17
CN105026413B (en)	2020-04-24
CN105026413A (en)	2015-11-04
AU2014203977A1 (en)	2015-07-09
ZA201504813B (en)	2017-11-29
KR20180053599A (en)	2018-05-23
EP2941436A2 (en)	2015-11-11
TW201718004A (en)	2017-06-01
WO2014107652A3 (en)	2014-12-24
CA3044471C (en)	2021-05-11
TW201429488A (en)	2014-08-01
EP2941436B1 (en)	2020-12-02
US10517936B2 (en)	2019-12-31
HK1213266A1 (en)	2016-06-30
EP3792272A1 (en)	2021-03-17
EP2941436A4 (en)	2016-07-27
US20200061169A1 (en)	2020-02-27
CN111499679A (en)	2020-08-07
KR101806370B1 (en)	2017-12-07
IL239785A0 (en)	2015-08-31
CL2015001902A1 (en)	2016-02-12
JP6781204B2 (en)	2020-11-04
JP2018141021A (en)	2018-09-13
US20150328299A1 (en)	2015-11-19
AU2014203977B2 (en)	2016-11-17
CL2015001900A1 (en)	2016-02-12
IL258728B (en)	2019-07-31
RU2015131033A (en)	2017-02-09
TWI611810B (en)	2018-01-21
CA2897084A1 (en)	2014-07-10
JP2016504385A (en)	2016-02-12
CA3044471A1 (en)	2014-07-10
TWI572356B (en)	2017-03-01
IL258728A (en)	2018-06-28
WO2014107652A2 (en)	2014-07-10
BR112015016381A2 (en)	2017-07-11
ES2843509T3 (en)	2021-07-19
AU2017200312A1 (en)	2017-02-02
KR20150111941A (en)	2015-10-06
CN111499679B (en)	2021-07-06
KR102084301B1 (en)	2020-03-03
IL239785B (en)	2018-05-31
US11752204B2 (en)	2023-09-12
JP6359561B2 (en)	2018-07-18
CA2897084C (en)	2019-07-16
PH12015501519A1 (en)	2016-04-18

Publication	Publication Date	Title
IL258728B (en)	2019-07-31	Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
HK1218928A1 (en)	2017-03-17	Cancer vaccines and vaccination methods
HK1223544A1 (en)	2017-08-04	Antibody formulations and methods
HK1211224A1 (en)	2016-05-20	Multivalent glycoconjugate vaccines
IL246401A0 (en)	2016-08-31	Anti-vista antibodies and fragments
HK1217107A1 (en)	2016-12-23	Alpha synuclein antibodies and uses thereof
HK1220470A1 (en)	2017-05-05	Anti-cd25 antibodies and their uses cd25
IL238864A (en)	2017-02-28	81-facet diamond with ten hearts and ten arrows structure inside
HK1220212A1 (en)	2017-04-28	Anti-cd25 antibodies and their uses cd25
HRP20191277T8 (en)	2019-11-01	Anti-cd26 antibodies and uses thereof
EP2968530A4 (en)	2016-04-06	Vaccines with biomolecular adjuvants
HK1218860A1 (en)	2017-03-17	Ovarian cancer vaccines and vaccination methods
EP3054972A4 (en)	2016-08-17	Vaccines with interleukin-33 as an adjuvant
IL244750A0 (en)	2016-04-21	Autologous tumor vaccines and methods
EP2968500A4 (en)	2016-06-29	Vaccines having an antigen and interleukin-23 as an adjuvant
DK2969005T3 (en)	2020-01-20	ATTENUATED INFLUENZAVIRA AND VACCINES
EP2951208A4 (en)	2016-10-19	Anti-cd83 antibodies and use thereof
ZA201407309B (en)	2016-05-25	Antigens and antigen combinations
EP2961427A4 (en)	2016-11-02	Hiv antigens and antibodies
TWM476314U (en)	2014-04-11	Touch-control structure and its manufacturing device
GB201310136D0 (en)	2013-07-24	Multivalent and monovalent vaccines
AU2013901875A0 (en)	2013-06-06	Immunogenic vaccines and uses thereof
GB201207385D0 (en)	2012-06-13	Antigens and antigen combinations
GB201207383D0 (en)	2012-06-13	Antigens and antigen combinations